Webinar | IMI2 JU – Call 23
Rules and procedures

30.06.2020
Agenda

- How to use GoToWebinar – Catherine Brett, IMI
- IMI rules and procedures – Elisabetta Vaudano, Fabrizio Federici, Desmond Barry, IMI
- Questions & answers
How to use GoToWebinar

- Expand / minimise control panel
- Microphone status
- Full screen
- Raise / lower your hand e.g. if you want to ask a question orally
- Send a question in writing
How to use GoToWebinar - audio

To listen via your computer, select **Computer audio**

Can’t hear us?
- Check your **speakers are switched on and not muted**
- Do a **Sound Check** to make sure GoToWebinar is picking up the right speakers
- Still not working? Select **Phone call** and dial the numbers given on your phone

To listen in via your phone, select **Phone call**, pick your country, and dial the numbers given

Can’t hear us?
- Check you have selected **Phone call** in the audio panel
- Try **another country’s** phone number
- Still not working? Select **Computer audio** and listen over your computer’s speakers
Before we start...

- This webinar is being recorded and will be published on the IMI website and/or IMI YouTube channel.
- Presentation slides will be published on the webinar web page.
- A participant list will be published on the website.
- IMI2 – Call 23 has been launched and all Call documents & details of how to apply can be found on the IMI website.

[IMI logo]
Rules and procedures for IMI2 Calls for proposals
Outline

1. Introducing IMI
2. Participation rules
3. Funding rules
4. Intellectual property rules
5. From Call to grant award
6. Writing a successful proposal
7. More information
Introducing IMI
Challenges in medicines development

Pre-clinical research

Closed & open innovation

Drug disc.  Pre-clinical

Pre-clinical research

5 000 compounds

10 000 compounds

250 compounds

5 therapies

1 therapy

Clinical Trials

Phase 1

Phase 2

Phase 3

No. patients / subjects

20-100

100-500

1000-5000

6 - 7 years

Regulatory review

Filing

Approval

HTA assessment

Price / reimbursement

2 – 5 years

Pharmaco-vigilance

Real world evidence
IMI – key concepts

- Non-competitive collaborative research
- Competitive Calls for proposals
- Open collaboration in public-private consortia
  - Data sharing, dissemination of results…
- Industry contribution is in kind
IMI2 budget (2014 – 2020)

IMI 2 total budget €3.276 billion

EU funding goes to:
Universities
SMEs
Mid-sized companies
Patient groups etc…

€1.638 bn

Other
€213 m

EFPIA companies receive no funding contribute to projects ‘in kind’

Associated Partners e.g. charities, non-EFPIA companies

EFPIA

€1.425 bn
IMI2 Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines

Aligned with WHO priorities
IMI life cycle

- Call topics definition
  - Scientific Research Agenda
  - Strategic Governing Groups
  - Annual Work Plan
  - Consultation Member-Associated States/Scientific Committee

- Call Launch / Evaluation / Grant award

- Project implementation
  Consortium agreement, Grant agreement, implementation and reporting
What does the typical IMI project look like?

Industrial partners align themselves around a real challenge for industry and agree to work together and commit resources.

New ideas from public sector, universities, SMEs etc. are needed to address the challenge.

Scale is a key to success and is provided by IMI funding and the outcomes should be transformative for the industry as well as having a clear “public” value.
A typical IMI consortium

- EFPIA
  - Pharma 1
  - Pharma 2
  - Pharma 3
  - Pharma 4
  - Pharma 5
  - Pharma 6

- Associated Partners
  - New for IMI2

- ACADEMIA

- SMALL AND MEDIUM-SIZED ENTERPRISES

- PATIENTS’ ORGANISATIONS

- HOSPITALS

- INDEPENDENT MID-SIZED COMPANIES (≤ €500m)

- REGULATORS
An international, cross-sector community

Over 11,500 researchers working for:
- open collaboration
- improved R&D productivity
- innovative approaches to unmet medical needs

597 Universities/Academic organisations

33 Patient groups

229 SMEs

61 EFPIA members

10 EFPIA partners in research

29 Regulators

15 Associated Partners

Connecting great minds
Why applying to IMI2 JU Call for proposals?

- Allow engagement in a cross-sector, multi-disciplinary consortium at the forefront of cutting-edge research
- Provide the necessary scale by combining funding, expertise, knowledge, skills and resources
- Build a trustful collaboration based on creativity and innovative and critical thinking
- Learn from each other - new knowledge, skills, ways of working
- Take part in transformative research that will make a difference in drug development and ultimately patients’ lives

IMI - ecosystem for innovative collaborations on shared challenges.
Introduction to IMI2 JU – Call 23
IMI2 JU Call 23 - topics

- Topic 1: Returning Clinical Trial Data to Study Participants within a GDPR compliant and approved ethical framework
- Topic 2: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
- Topic 3: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
- Topic 4: Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence
- Topic 5: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies
- Topic 6: Behavioural Model of Factors Affecting Patient Adherence
IMI 2 JU - Call 23 two stages

- Date of Call launch: 23 June 2020

- Calls text and documents are published on the:
  IMI2 JU website and the Funding and Tenders Portal

- **Deadline for Short Proposal submission**: 29 September 2020 (17:00:00 Brussels time)

- Deadline for Full Proposal submission: 17 March 2021 (17:00:00 Brussels time)

- Webinar topic presentations and recordings will be available from the IMI website.
Call 23 – two stages

- At stage 1 evaluation the budget is evaluated under criterion 3 ‘Quality and Efficiency of the Implementation’
- Applicants will need to provide a breakdown of costs (and not only the overall amount, as previously the case), by filling in the budget table in Part A of the proposal

Budget for the proposal

<table>
<thead>
<tr>
<th>Participant</th>
<th>Country</th>
<th>(A) Direct personnel costs €</th>
<th>(B) Other direct costs €</th>
<th>(C) Direct costs of subcontracting €</th>
<th>(D) Direct costs of providing financial support to third parties €</th>
<th>(E) Costs of in-kind contributions not used on the beneficiary's premises €</th>
<th>(F) Indirect Costs / € (=0.25(A+B-E))</th>
<th>(G) Special unit costs covering direct &amp; indirect costs / €</th>
<th>(H) Total eligible costs / € (=A+B+C+D+F+G)</th>
<th>(I) Reimbursement rate (%)</th>
<th>(J) Max. EU Contribution / € (=H*I)</th>
<th>(K) Requested EU Contribution / €</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total: 0 0 0 0 0 0 0 0 0 0 0 0 0

IMI | Innovative Medicines Initiative
Call 23

Applicants must use the electronic submission service which is under the Funding and Tenders Portal:

https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home

- To access the portal and submit a proposal, applicants must have:
  - An **EU Login account** (previously, ‘ECAS’ account)
  - Their **organisation registered** on the Participant Portal Beneficiary Register, with a 9-digit **Participant Identification Code (PIC) number**

If you do not have an EU Login account yet, you can create an EU Login account on the Funding and Tenders Portal, and register your organisation.

Participation rules
A single set of rules

- Covering all H2020 research and innovation actions
- Adaptability where needed:
  - Entities eligible for funding
  - IP

EU Financial Regulation
Specific rules for participation

COSME

etc.
Conditions for Call 23 two-stages

H2020 Rules for participation apply to IMI2 JU Call for Proposals and Actions except where specifically derogated

- **Minimum conditions**
  - **RIA:** at least three independent legal entities, each established in a different EU Member State or H2020 associated country

- **Two-stages**
  - Stage 1 SPs from applicants requesting JU funding (30 page limit)
  - Stage 2 merging 1st-ranked SPs with industry consortia (70 page limit)

- **Evaluation criteria**
  - At stage 1, all 3 criteria are evaluated (including budget)
  - Evaluation criteria, thresholds and Proposal templates have been revised as of Call 18
  - Threshold is 3 for each of the evaluation criteria ‘excellence’, ‘impact’ and ‘quality and efficiency of the implementation’
  - the overall threshold is 10
Conditions for Call 23 two-stages

- **Submission tool**
  SPs/FPs to be submitted through the Electronic Submission Service under the Funding and Tenders Portal

- **Submission deadlines**
  Established in the Call topic text both for stage 1 and 2

- **Indicative contribution**
  For each topic, the maximum JU contribution and the estimated industry contributions are set in the call text

- **Hearings**
  If necessary, at stage 1 hearings might be organised with applicants during panel meetings. After submission deadline, coordinators will be informed about the possible date for the hearing (check SP details!)
Conditions for Call 23 two-stages

- **Information on the outcome of the evaluation:**
  Information to the applicants - max 5 months from submission deadline
  N.B. GA signature is expected by Q3 2021, specific timelines will be provided after stage 2.

- **Financial Support to Third Parties**
  Where relevant, applicants should develop in FPs open, transparent, objective processes and criteria for the allocation of financial support in accordance to Annex K of the H2020 WP and article 15 of the IMI2 JU MGA

- **Plan for exploitation and dissemination**
  It must be included in 2nd stage Full proposals

**NB:** Contacts/discussions about a given topic between potential applicant consortia and members of the industry consortium are prohibited throughout the procedure until the results of the first stage evaluation.
Attracting stakeholders

Any legal entity, regardless its place of establishment, carrying out work relevant to the Call objectives may be part of applicant consortia

But… not all participating entities are eligible for funding
Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises (≤ €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:
- EU Member State
- Associated Country

Other countries: No funding unless participation deemed essential by IMI2 JU for carrying out the action

Art.1 Commission Delegated Regulation (EU) No 622/2014
Expected consortia – Call 23

Stage 1 of two stage - Short Proposals

- Consortia consisting of:
  - IMI2 JU fundable legal entities carrying out activities relevant for achieving the project objectives
  - additional legal entities carrying out activities relevant for achieving the project objectives.
Expected consortia Call 23

Stage 2 of two stage – Full Proposals

- One Full Consortium per topic consisting of:
  - 1\textsuperscript{st} ranked SP consortium - IMI2 JU fundable legal entities/additional legal entities
  - Industry consortium (EFPIA companies and IMI2 JU Associated Partners) associated to the relevant topics
Funding rules
IMI2 JU Funding model

- IMI2 JU is a PPP, actions are normally co-funded by:
  - JU funding to BRFs (beneficiaries receiving funding = legal entities eligible for funding)
  - In-kind/cash contribution from BNRFs (beneficiaries not receiving funding):
    - EFPIA constituents and affiliates
    - IMI2 JU Associated Partner

Other legal entities may also participate as BNRFs at their own cost
One single funding rate per project - BRFs

One project = One rate
For all beneficiaries and all activities

- 100% of the direct eligible costs
- Indirect costs: 25% flat rate
JU contribution to BRFs covers:

- **Personnel**
  - Wider acceptance of average personnel costs
  - Acceptance of supplementary payments
    - For non-profit organisations of up to 8000 euros/year/person
  - Less requirements for time records
- **Equipment, consumables, travels…**
- **Subcontracting**

Considering BRFs accounting and management principles

- **BRFs (only) may also receive Financial contribution from EFPIA/APs**
  - to be reported as receipts
Third party is a legal entity which carries out work of the action, supplies goods or provide services for the action, but which did not sign the grant agreement

Types of third parties:

1. Third parties directly carrying out part of the work described in Annex 1 of the GA

2. Other third parties: providing resources, goods or services to beneficiaries carrying out the work described in Annex 1

3. Third parties receiving financial support (money) from the beneficiary as part of the action, subject to specific conditions, i.e. Annex K H2020 WP
## Overview different types of third parties in GA

<table>
<thead>
<tr>
<th>TYPE</th>
<th>Works on action tasks?</th>
<th>Provides resources or services for action?</th>
<th>What is eligible?</th>
<th>Must be indicated in Annex 1?</th>
<th>Indirect costs?</th>
<th>Selecting the third party</th>
<th>GA articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linked third party</td>
<td>YES</td>
<td>NO</td>
<td>Costs</td>
<td>YES</td>
<td>YES</td>
<td>Must be affiliated or have a legal link and be eligible for funding</td>
<td>Article 14</td>
</tr>
<tr>
<td>International partners</td>
<td>YES</td>
<td>NO</td>
<td>N/A</td>
<td>YES</td>
<td>N/A</td>
<td>Must not be eligible for funding</td>
<td>Article 14a</td>
</tr>
<tr>
<td>Subcontractor</td>
<td>YES</td>
<td>NO</td>
<td>Price</td>
<td>YES</td>
<td>NO</td>
<td>Must be best value for money, avoid conflict of interest</td>
<td>Article 13</td>
</tr>
<tr>
<td>Third party providing in-kind contribution</td>
<td>NO</td>
<td>YES</td>
<td>Costs</td>
<td>YES</td>
<td>YES</td>
<td>May not be used to circumvent the rules</td>
<td>Articles 11 and 12</td>
</tr>
<tr>
<td>Contractor (selling, equipment, good or service)</td>
<td>NO</td>
<td>YES</td>
<td>Price</td>
<td>NO</td>
<td>YES</td>
<td>Must be best value for money, avoid conflict of interest</td>
<td>Article 10</td>
</tr>
<tr>
<td>Third parties receiving financial support</td>
<td>The third parties participate in the action as recipients.</td>
<td>Amount of support given</td>
<td>YES</td>
<td>NO</td>
<td>According to the conditions in Annex 1</td>
<td>Article 15</td>
<td></td>
</tr>
</tbody>
</table>
EFPIA and Associated Partners contribution - BNRFs

- EFPIA companies
- Other industries and partners (= Associated Partners to IMI2)
  - In-kind (actual direct and indirect costs or average FTE) and/or financial contributions (FC)*
  - Based on the usual management principles and accounting practices
  - Contributions from affiliated entities as part of in-kind

* Recipient of FC must be BRFs, i.e. eligible for JU funding

When relevant to IMI2 JU objectives: non-EU in-kind contribution (up to 30% at programme level)

Annual financial reporting is disconnected from GA periodic reports
Deadlines for reporting

- Scientific reporting (full consortium) due at project deadlines (i.e. GA), duration reporting period: 12 months
- Financial reporting for:
  - Beneficiaries receiving JU funding, due at project deadlines (i.e. GA)
  - CFS: >EUR 325k at project end
  - Beneficiaries Not receiving funding (e.g. EFPIA companies and APs),
  - due by 31 Jan - certification by 30 April - covering previous calendar year
IMI2 JU’s Intellectual Property (IP) rules
One set of rules for multiple interests

Support to industry

Incentive to participate

Freedom of access

Dissemination of information

Compensation for IP

Flexibility + trusted party
Background vs. Results

**Background**
Any data, know-how or information including any rights such as IP:
1) held before GA
2) needed for action or exploit the results
3) identified and agreed

**Results**
Any output (data, knowledge or information etc) generated in the action, as rights attached to it, including IP

**Access rights to Results**

**Access rights to Background**

**Sideground**
Any data, know-how or information including any rights such as IP generated during the action but outside of its objectives and not needed for implementation or Research Use => Importance of Action objectives
Ownership of results

Results are owned by the beneficiary that generates them.

Possible transfer of ownership of Results only after their generation:
- Pre-allocation of ownership \textbf{NO}
- Prior agreement on transfer after generation \textbf{YES}
Protection of results

Mandatory for beneficiaries receiving funding

- lies with the owner(s) in adequate and effective manner based on relevant (national) legal provisions, action peculiarities, type of result and legitimate interests
- Type of protection to be reported to the JU
- if valuable results left unprotected, to be discussed within the consortium and inform JU
Access Rights

*Articles 25 IMI2 MGA (to background) and 31 IMI2 MGA (to results)*

- Access rights = rights to use
- Mandatory written request
- Access rights are in principle not sub licensable but beneficiaries may agree in the consortium agreement to define certain situations where sublicense apply => Traceability
- Time limit to request access rights
  - No minimum/maximum
  - Consistent with particular project/results/background
Mandatory access rights: right to use

Background
Access rights to beneficiaries
- for action implementation (including to affiliated entities)
  - If needed for research use of results

Results
Access rights to beneficiaries:
- for action implementation (including to affiliated entities)
  - For research use of results

Background
Access rights to third parties:
- after completion of the action
  - if needed for research use of results
  - possibility to exclude certain elements

Results
Access rights to third parties:
- after completion of the action
  - within established time limits
  - for research use of results
Purposes of Access Rights:
Research Use vs. Direct Exploitation

**Research Use**
- Use of results or background necessary to use the results for all purposes other than for completing the action or for direct exploitation
- The application of results (like an animal model or a biomarker) as a tool for research and clinical research in the discovery or development (as the case may be for commercialisation) of pharmaceutical products by for-profit institutions and organisations

**Direct Exploitation**
- Development for commercialisation or to commercialise the results
- Commercialisation of such biomarker itself as a diagnostic kit would be direct exploitation
## Access Rights conditions

<table>
<thead>
<tr>
<th>Access rights granted by a beneficiary to/on</th>
<th>Background (necessary and identified)</th>
<th>Results</th>
<th>Sideground</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beneficiaries for completion of the action</td>
<td>Royalty-free</td>
<td>Royalty-free</td>
<td>N.A.</td>
</tr>
<tr>
<td>Beneficiaries and affiliates for Research Use</td>
<td>Fair &amp; reasonable conditions (e.g. Royalty-free conditions)</td>
<td>Fair &amp; reasonable conditions (e.g. Royalty-free conditions)</td>
<td>N.A.</td>
</tr>
<tr>
<td>Third Parties for Research Use after the action</td>
<td>Appropriate conditions</td>
<td>Appropriate conditions</td>
<td>N.A.</td>
</tr>
<tr>
<td>Beneficiaries and affiliates or Third Parties for Direct Exploitation</td>
<td>To be negotiated</td>
<td>To be negotiated</td>
<td>N.A.</td>
</tr>
</tbody>
</table>
Dissemination modalities

Each beneficiary has the obligation to disseminate its own results

- As soon as reasonably practicable
- For publications: Open access is mandatory
- Mandatory to mention IMI support & EFPIA in-kind contribution in patent applications / all communications & dissemination

Open Access to Publications
(Article 29.2 GA)
Deposit in repositories and publishing in Open Access (OA).
OA charges may be considered eligible costs.

Open Research Data (ORD)
(Article 29.3 GA)
IMI2 projects are part of the ORD:
- ‘underlying data to published results’ generated in the project, and any other data.
‘As open as possible as closed as necessary’: balance between openness and protection of scientific information and IPR.

Data Management Plan (DMP) (AWP)
All projects need to develop and update a DMP, even if opted out from the ORD.
DMPs should aim to produce ‘FAIR’ data:
Findable
Accessible
Interoperable
Re-usable
Reference documents

- **H2020 Rules for Participation**
  - IPR section: Article 1.3.c and Articles 41 to 49

- **IMI2 – EC Delegated Regulation**
  - IPR section: Articles 2 to 7

- **IMI2 model Grant Agreement** (revised November 2017)
  - IPR section: Articles 23a to 31

- **IMI2 annotated Grant Agreement**

[Website Link]
From Call to grant award
IMI2 JU Call 23 two-stages

**Topic definition**
- Industry Assoc partners

**Identification of topics and willingness to collaborate**
- Applicant consortia submit short proposals

**Stage 1**
- Applicant consortia submit short proposals
  - Academic
  - Hospitals
  - Mid-size enterprises
  - Regulators
  - Patients’ organisations
  - SMEs

**Stage 2**
- Full consortium submits full proposal
  - Applicant consortium
  - Industry APs

**Grant award**
- Consortium Agreement
- Grant Agreement

**Evaluation**
- Call launch
- Merger: applicants & industry
- Finalisation

**Project launch!**

---

**Call launch**

---

**Merger: applicants & industry**

---

**Finalisation**

---

**Project launch!**
A single set of evaluation criteria

- As of Call 18, the evaluation criteria, thresholds and proposal templates have been revised
- Two-stage evaluation: all three criteria considered at both stages
- Thresholds and weighting in the Call documents depending two-stages/single stage
- Minimum of 3 independent experts

Each proposal evaluated ‘as it is’, not as ‘what could be’
Keeping the momentum

Maximum Time To Grant: 8 months from submission of full proposal:

N.B. Call 23 GAs expected to be signed by end of Q3 2021

5 months for informing applicants of scientific evaluation

3 months for signature of grant agreement

NEW Legal entity validated in parallel
IMI2 JU Grant Agreement

- The new IMI2 JU MGA (v.5) will apply to Call 23
- It follows H2020 Model Grant Agreement (v.5) with IMI2 specificities.
- IMI2 JU Annotated Model Grant Agreement v.2.2 (based upon H2020 AGA v.5.2)
- It is e-signed between IMI2 JU and Coordinator only. Other beneficiaries e-sign Accession Forms
- EFPIA and Associated Partners are beneficiaries not receiving funding (BNRFs, Art.9) - their financial report occurs outside the GA, for more info please consult 'IMI2 JU guidelines for reporting in kind and financial contributions by Members other than the Union and Associated Partners'
IMI2 Grant Agreement

Article 41.3 - Consortium agreement *may cover*:

- *internal organisation of the consortium, including allocation of scientific tasks among beneficiaries*

Scientific Project Leadership

Scientific Project Leader may be different from Coordinator to:

- reflect the *spirit of industrial co-leadership* in call topics built upon EFPIA/industry scientific priorities

- address the need for strong scientific coordination and collaboration between BRFs (JU funded) and BNRFs (industry)

*IMI2 specificities are presented in the IMI2 JU AGA*
Consortium agreement

- Contractual arrangement **between all participants** to set out their rights and obligations, especially governance, liability and IPR

- Shall comply with the **IMI2 JU Model Grant Agreement**

- To be agreed before the signature of the GA, IMI2 JU is not a party

- **To be adapted to the specific needs of each IMI action!**

- A template prepared by EFPIA shows what a consortium agreement might look like:
  

Consortia may also use alternative templates if they wish.
Tips for success
Common Mistakes

- Admissibility/Eligibility criteria not met:
  - Submission **deadline** missed
  - Proposal **out of scope**
    (if you have doubts on how to respond to the Call contact us)
  - Not involving at least **three independent legal entities** (RIA) from **three** different MS/AC
Common Mistakes

- The proposal does not address all the **objectives** (in some cases proposals have nothing to do with the topic!)
- Submitted text does not respect the proposal template (sometimes received even slides!)
- Ensure to follow the instructions of the proposal template
- Applicants do not have the **capabilities** to address all of the objectives or there is redundancy between partners
- A proposal is scientifically excellent but will have **limited impact**
- **Budget**, either over-estimated or not fully justified
- **Ethical issues** not addressed
Tips

- Read all the Call-relevant material that is provided on the IMI website – www.imi.europa.eu
- Understand IMI2 JU rules and respect them
- Consider the PPP dimension of the action (e.g. Governance, industry contribution vs IMI2 JU funding)
- If in doubt, ask a member of the Programme Office
- Your proposal should provide reviewers with all the information requested to allow them to evaluate it
- Start working early (pre-materials available before)
- Dedicate sufficient time to submit the proposal: create an EU login account, obtain a PIC number - don’t wait until the last day to start the submission process
- More tips: www.imi.europa.eu/content/tips-applicants
Submitting a proposal

Via the **new** Funding and Tenders Portal

https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home
Submitting a proposal

Look for IMI2 JU Calls, you will find the links to start the submission of a proposal:
Proposal Submission Form - Part A

Please indicate only one of the following options if applicable to your organisation

- Companies (including micro enterprises and SMEs) with an annual turnover up to EUR 500 millions which are not affiliated entities of companies with an annual turnover of more than EUR 500 millions
- Patients Organisation
- Regulatory Agency
- Member of EFPIA not requesting funding
- IMI2 Associated Partners to this topic not requesting funding
- Any other organisation not requesting funding

*Certain type of organisations are not covered by the above options, in that case none should be selected*

- Where applicable, the organisation type has to be indicated (see above):
  - Applies to the 6 types of organisations identified in the form;
  - If none of the options is selected, the system generates a warning;
  - The warning is not blocking the submission of the proposal.
Proposal Submission Form - Part A

When validating the forms, different warnings appear (see above):
- The yellow warnings don’t block the submission of the proposal;
- Only the warnings flagged in red will block the submission of the proposal.
Proposal Submission Form - Part A

4 - Call specific questions

**Essential information to be provided for proposals including clinical Trials / studies / investigations**

 Applies to proposals including clinical trials / studies / investigations

<table>
<thead>
<tr>
<th>Are clinical studies / trials / investigations included in the work plan of this project?</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

Please upload the dedicated annex 'Essential information for clinical studies / trials / investigations' (a Word template is provided under 'download templates' in the upload section for Part B and Annexes).

This document should include the relevant information of each clinical study / trial / investigation included in the work plan of this project.

<table>
<thead>
<tr>
<th>Please give a short title, an acronym or a unique identifier to each clinical study / trial / investigation, to be used as a reference/ identifier in the other parts of the proposal.</th>
</tr>
</thead>
</table>

- If the proposal includes clinical trials/studies/investigations, in stage one of two-stages calls, the specific annex is not requested (see above the section):
  - In stage one relevant aspects should be integrated in part B of the proposal template;
  - The dedicated annex is compulsory in stage two (see Clinical trial template).
More information
Stay in touch

- Visit our new website www.imi.europa.eu
- Sign up to our newsletter via the website
- Follow us on Twitter @IMI_JU
- Join our LinkedIn group bit.ly/LinkedInIMI
- E-mail us infodesk@imi.europa.eu
Your contact points

At the IMI Programme Office

- General queries: applicants@imi.europa.eu
- IP queries: IMI-IP-Helpdesk@imi.europa.eu

Local contacts

- IMI2 JU States Representatives Group: bit.ly/IMISRG
- Horizon 2020 Health National Contact Points: bit.ly/H2020_NCPs
Thank you
Questions
Questions?

Raise your hand if you want to ask a question orally

Send a question in writing

After the webinar, send any questions to the IMI Programme Office

applicants@imi.europa.eu